Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12435149 | 1.00 | DPP4 (0.44) | DPP4F2LMNAADRA2AADRA2C | |
| SCHEMBL12729962 | 0.78 | DPP4 (0.50) | DPP4F2LMNAADRA2AADRA2C | |
| SCHEMBL8643386 | 0.78 | DPP4 (0.50) | DPP4F2LMNAADRA2AADRA2C | |
| SCHEMBL16062547 | 0.76 | L3MBTL1 (0.54) | LMNATDP1L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL3262994 | 0.76 | DPP4 (0.48) | DPP4F2LMNAADRA2AADRA2C | |
| SCHEMBL4631540 | 0.74 | LMNA (0.56) | LMNAADRA2CTDP1L3MBTL1KDM4E | |
| SCHEMBL16838683 | 0.74 | ADRA2A (0.46) | DPP4F2LMNAADRA2AADRA2C | |
| SCHEMBL4662816 | 0.74 | LMNA (0.47) | F2LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL5975716 | 0.74 | ADRA2A (0.46) | DPP4F2LMNAADRA2AADRA2C | |
| SCHEMBL8201163 | 0.74 | ADRA2A (0.46) | DPP4F2LMNAADRA2AADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0132764-A2 | Derivatives of dihydrodibenzocycloheptylidene-ethylamine | SOCIEDAD ESPANOLA DE ESPECIALIDADES FARMACO-TERAPEUTICAS, S.A. (ES) | 1985-02-13 | — | — | EP | claimed |
| JP-52142051-A | — | — | None | — | — | JP | disclosed |
| US-8268894-B2 | Compositions and methods for the treatment of infectious diseases | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-09-18 | — | — | US | disclosed |
| US-20110118307-A1 | Compositions and methods for the treatment of infectious diseases | GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2011-05-19 | — | — | US | disclosed |
| US-7456222-B2 | Anti tubercular drug: compositions and methods | SEQUELLA, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| EP-0250254-B1 | CIS & TRANS STILBENES AND THEIR COMPOSITION FOR THE TREATMENT OF HYPERTENSION | McNeilab, Inc. (US) | 1991-06-19 | — | — | EP | disclosed |
| EP-0250254-A1 | Cis & trans stilbenes and their composition for the treatment of hypertension | McNeilab, Inc. (US) | 1987-12-23 | — | — | EP | disclosed |
| EP-0132764-A2 | Derivatives of dihydrodibenzocycloheptylidene-ethylamine | SOCIEDAD ESPANOLA DE ESPECIALIDADES FARMACO-TERAPEUTICAS, S.A. (ES) | 1985-02-13 | — | — | EP | disclosed |
| EP-0132764-A2 | Derivatives of dihydrodibenzocycloheptylidene-ethylamine | SOCIEDAD ESPANOLA DE ESPECIALIDADES FARMACO-TERAPEUTICAS, S.A. (ES) | 1985-02-13 | — | — | EP | disclosed |
| JP-S52142051-A | 1,2-DIPHENYLALKYLAMINE DERIVATIVES AND THEIR PREPARATION | RES INST FOR PROD DEV | 1977-11-26 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118307-A1 | Compositions and methods for the treatment of infectious diseases | TERT, C5, ELANE | DPP4 2300/4885F2 1669/4885LMNA 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.